365 related articles for article (PubMed ID: 27766914)
1. N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects.
Minarini A; Ferrari S; Galletti M; Giambalvo N; Perrone D; Rioli G; Galeazzi GM
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):279-292. PubMed ID: 27766914
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.
Deepmala ; Slattery J; Kumar N; Delhey L; Berk M; Dean O; Spielholz C; Frye R
Neurosci Biobehav Rev; 2015 Aug; 55():294-321. PubMed ID: 25957927
[TBL] [Abstract][Full Text] [Related]
3. The promise of N-acetylcysteine in neuropsychiatry.
Berk M; Malhi GS; Gray LJ; Dean OM
Trends Pharmacol Sci; 2013 Mar; 34(3):167-77. PubMed ID: 23369637
[TBL] [Abstract][Full Text] [Related]
4. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.
Dean O; Giorlando F; Berk M
J Psychiatry Neurosci; 2011 Mar; 36(2):78-86. PubMed ID: 21118657
[TBL] [Abstract][Full Text] [Related]
5. What Future Role Might N-Acetyl-Cysteine Have in the Treatment of Obsessive Compulsive and Grooming Disorders?: A Systematic Review.
Smith L; Tracy DK; Giaroli G
J Clin Psychopharmacol; 2016 Feb; 36(1):57-62. PubMed ID: 26629962
[TBL] [Abstract][Full Text] [Related]
6. [The application of N-acetylcysteine in optimization of specific pharmacological therapies].
Hołyńska-Iwan I; Wróblewski M; Olszewska-Słonina D; Tyrakowski T
Pol Merkur Lekarski; 2017 Sep; 43(255):140-144. PubMed ID: 28987048
[TBL] [Abstract][Full Text] [Related]
7. Clinical applications of N-acetylcysteine.
Kelly GS
Altern Med Rev; 1998 Apr; 3(2):114-27. PubMed ID: 9577247
[TBL] [Abstract][Full Text] [Related]
8. N-acetylcysteine as a new prominent approach for treating psychiatric disorders.
Smaga I; Frankowska M; Filip M
Br J Pharmacol; 2021 Jul; 178(13):2569-2594. PubMed ID: 33760228
[TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility.
Dodd S; Dean O; Copolov DL; Malhi GS; Berk M
Expert Opin Biol Ther; 2008 Dec; 8(12):1955-62. PubMed ID: 18990082
[TBL] [Abstract][Full Text] [Related]
10. N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence.
Ooi SL; Green R; Pak SC
Biomed Res Int; 2018; 2018():2469486. PubMed ID: 30426004
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness of N-acetylcysteine in the treatment of schizophrenia].
Miyake N; Miyamoto S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Apr; 36(2):29-35. PubMed ID: 27333656
[TBL] [Abstract][Full Text] [Related]
12. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities.
Bavarsad Shahripour R; Harrigan MR; Alexandrov AV
Brain Behav; 2014 Mar; 4(2):108-22. PubMed ID: 24683506
[TBL] [Abstract][Full Text] [Related]
13. [N-Acetylcysteine: new possibilities to use an old substance].
Ahola T; Lapatto R
Duodecim; 1999; 115(4):375-9. PubMed ID: 11830885
[No Abstract] [Full Text] [Related]
14. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder.
Wink LK; Adams R; Wang Z; Klaunig JE; Plawecki MH; Posey DJ; McDougle CJ; Erickson CA
Mol Autism; 2016; 7():26. PubMed ID: 27103982
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of N-acetylcysteine on retinal degeneration in two mouse models of normal tension glaucoma.
Sano H; Namekata K; Kimura A; Shitara H; Guo X; Harada C; Mitamura Y; Harada T
Cell Death Dis; 2019 Jan; 10(2):75. PubMed ID: 30692515
[TBL] [Abstract][Full Text] [Related]
16. N-acetylcysteine targets 5 lipoxygenase-derived, toxic lipids and can synergize with prostaglandin E
Karuppagounder SS; Alin L; Chen Y; Brand D; Bourassa MW; Dietrich K; Wilkinson CM; Nadeau CA; Kumar A; Perry S; Pinto JT; Darley-Usmar V; Sanchez S; Milne GL; Pratico D; Holman TR; Carmichael ST; Coppola G; Colbourne F; Ratan RR
Ann Neurol; 2018 Dec; 84(6):854-872. PubMed ID: 30294906
[TBL] [Abstract][Full Text] [Related]
17. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why.
Aldini G; Altomare A; Baron G; Vistoli G; Carini M; Borsani L; Sergio F
Free Radic Res; 2018 Jul; 52(7):751-762. PubMed ID: 29742938
[TBL] [Abstract][Full Text] [Related]
18. Cognitive effects of adjunctive N-acetyl cysteine in psychosis.
Rapado-Castro M; Dodd S; Bush AI; Malhi GS; Skvarc DR; On ZX; Berk M; Dean OM
Psychol Med; 2017 Apr; 47(5):866-876. PubMed ID: 27894373
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia.
Bulut M; Savas HA; Altindag A; Virit O; Dalkilic A
World J Biol Psychiatry; 2009; 10(4 Pt 2):626-8. PubMed ID: 19735056
[TBL] [Abstract][Full Text] [Related]
20. ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis.
Cotton SM; Berk M; Watson A; Wood S; Allott K; Bartholomeusz CF; Bortolasci CC; Walder K; O'Donoghue B; Dean OM; Chanen A; Amminger GP; McGorry PD; Burnside A; Uren J; Ratheesh A; Dodd S
Trials; 2019 Nov; 20(1):658. PubMed ID: 31779696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
